New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

The ABCs of Optimizing Drug Sequencing for IBD

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

Study Looks at Infection Risk in Older IBD Patients on Immunosuppressive Therapies

Older adults represent a growing segment of patients with IBD, and several unique factors should be considered when ...

AUGUST 30, 2024

Good News for Maintenance Therapies in IBD

Both studies in this month’s The Regueiro Report are about interleukin inhibitors: risankizumab and ...

JULY 16, 2024

FDA Approves Pyzchiva Biosimilar to Stelara

Pyzchiva was approved for all indications of its reference biologic; the FDA provisionally determined that ...

JULY 3, 2024

IBD Stories Matter: Rethinking First-Line Therapy For Moderate to Severe Stricturing Crohn’s Disease

Experts discuss tough cases in inflammatory bowel disease and how they would treat them if the patient was in front ...

NOVEMBER 15, 2023

More Insight Into Anti-Interleukins

This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically ...

SEPTEMBER 11, 2023

Similar Results With Tofacitinib, Ustekinumab After Biologic Failure in Patients With UC

In biologic-experienced patients with ulcerative colitis, tofacitinib and ustekinumab achieve similar rates of ...

JUNE 26, 2023

Registry Data Show Vedolizumab, Ustekinumab Safe in Pregnancy

Patients being treated with vedolizumab or ustekinumab for inflammatory bowel disease who are pregnant or are ...

APRIL 5, 2023